Valuable lessons are learned when experienced business development executives draw from their dealmaking experience and dive into some of the common and not so common pitfalls in partnering. Read more »
A few nimble VCs and entrepreneurs are developing funds and corporate structures that may once again make private biotech companies attractive investments. Companies changing the game have one common theme: they focus on the drug, not the company. Read more »
There is a rising interest in assets in some of the most sought-after therapeutic areas: those where access is all but assured, patients are more easily identified, and the commercial call-point is narrow. Read more »
Biotech/pharma licensing deals face many challenges, not the least of which is the possibility of deal termination due to lack of efficacy, safety or due diligence concerns; many deals come to an end for reasons that are completely outside the control of the biotech partner. Read more »
Nycomed fielded several offers before Takeda landed the prize that resulted in one of 2011′s most significant deals. In this exclusive, Anton Gueth of Gueth Consulting interviews two of the deal’s prime movers, Catherine Sazdanoff of Takeda and Gunnar Gardemyr of Nycomed, to learn how and why this big deal came together. Read more »
Every indicator is pointing toward a scenario where future health outcomes will depend on non-traditional partnerships and alliances, including a growing need for collaboration with companies with data management and analytics expertise. Patrick Flochel, EMEIA Life Sciences Leader/Partner at Ernst & Young, leads a group discussion that focuses on the individual patient in a more holistic approach to improve health outcomes. Read more »
The pace of regenerative medical research and technological breakthroughs has accelerated over the past 20 years and recent technological advances have made stem cell treatment a clinical reality, but what significant breakthroughs are coming in the next three to five years? Read more »
Moderator Steve Dickman, CEO of @cbtadvisors, and a panel of social-media-savvy dealmakers engaged in a lively roundtable discussion about using social media to help achieve your business objectives. They cover topics such as which social media platforms are acceptable for which types of activities and how to position yourself and your company through social media. Read more »
Newsletter